Clinical Trial Update: Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for MEDI-573 in combination with standard endocrine therapy in hormone-sensitive, HER2-negative metastatic breast cancer; study co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Her-2 Negative Metastatic Breast Cancer

Drugs mentioned

• MEDI-573

Snippet

Sponsor: MedImmune LLC | Conditions: Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-08-28